Skip to main content
Have a personal or library account? Click to login
Correlation of diffusion MRI with the Ki-67 index in non-small cell lung cancer Cover

Correlation of diffusion MRI with the Ki-67 index in non-small cell lung cancer

Open Access
|Aug 2015

References

  1. 1. Yabuuchi H, Hatakenaka M, Takayama K, Matsuo Y, Sunami S, Kamitani T, et al. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging.2011;598-604.
  2. 2. Wang Y, Chen ZE, Yaghmai V, Nikolaidis P, McCarthy RJ, Merrick L, et al. Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics.2011;1071-9.
  3. 3. Zhang J, Cui LB, Tang X, Ren XL, Shi JR, Yang HN, et al. DW MRI at 3.0 T versus FDG PET/CT for detection of malignant pulmonary tumors.2014;606-11.
  4. 4. Li F, Yu T, Li W, Zhang C, Cao Y, Su D, et al. Correlation of apparent diffusion coefficient with histologic type and grade of lung cancer.2012;646-51.
  5. 5. Xu L, Tian J, Liu Y, Li C. Accuracy of diffusion-weighted (DW) MRI with background signal suppression (MR-DWIBS) in diagnosis of mediastinal lymph node metastasis of nonsmall-cell lung cancer (NSCLC).2014;200-5.
  6. 6. Usuda K, Sagawa M, Motono N, Ueno M, Tanaka M, Machida Y, et al. Diagnostic performance of diffusion weighted imaging of malignant and benign pulmonary nodules and masses: comparison with positron emission tomography.2014;4629-35.
  7. 7. Türkbey B, Aras Ö, Karabulut N, Turgut AT, Akpinar E, Alibek S, et al. Diffusion-weighted MRI for detecting and monitoring cancer: a review of current applications in body imaging.2012;46-59.
  8. 8. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology.2007;1622-35.
  9. 9. Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.2009;102-25.
  10. 10. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown.2000;311-22.
  11. 11. Raĭkhlin NT, Bukaeva IA, Smirnova EA, Gurevich LE, Delektorskaia VV, Polotskiĭ BE, et al. Significance of the expression of nucleolar argyrophilic proteins and antigen Ki-67 in the evaluation of cell proliferative activity and in the prediction of minimal (T1) lung cancer.2008;15-18.
  12. 12. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.1984;1710-15.
  13. 13. Zhu L, Ren G, Li K, Liang ZH, Tang WJ, Ji YM, et al. Pineal parenchymal tumours: minimum apparent diffusion coefficient in prediction of tumour grading.2011;1456-63.
  14. 14. Choi SY, Chang YW, Park HJ, Kim HJ, Hong SS, Seo DY. Correlation of the apparent diffusion coefficiency values on diffusion-weighted imaging with prognostic factors for breast cancer.2012;e474-9.
  15. 15. Onishi N, Kanao S, Kataoka M, Iima M, Sakaguchi R, Kawai M, et al. Apparent diffusion coefficient as a potential surrogate marker for Ki-67 index in mucinous breast carcinoma,2015;610-5.
  16. 16. Mesko S, Kupelian P, Demanes DJ, Huang J, Wang PC, Kamrava M. Quantifying the ki-67 heterogeneity profile in prostate cancer.2013:717080
  17. 17. Kobayashi S, Koga F, Kajino K, Yoshita S, Ishii C, Tanaka H, et al. Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer.2014;172-8.
  18. 18. Tang Y, Dundamadappa SK, Thangasamy S, Flood T, Moser R, Smith T, et al. Correlation of apparent diffusion coefficient with Ki-67 proliferation index in grading meningioma.2014;1303-8.
  19. 19. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis.2004;2018-25.
  20. 20. Usuda K, Zhao XT, Sagawa M, Aikawa H, Ueno M, Tanaka M, et al. Diffusion-weighted imaging (DWI) signal intensity and distribution represent the amount of cancer cells and their distribution in primary lung cancer.2013;265-72.
  21. 21. Ohno Y, Koyama H, Yoshikawa T, Matsumoto K, Aoyama N, Onishi Y, et al. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with nonsmall cell lung cancer receiving chemoradiotherapy.2012;75-82.
  22. 22. Tanaka R, Horikoshi H, Nakazato Y, Seki E, Minato K, Iijima M, et al. Magnetic resonance imaging in peripheral lung adenocarcinoma: correlation with histopathologic features.2009;4-9.
  23. 23. Matoba M, Tonami H, Kondou T, Yokota H, Higashi K, Toga H, et al. Lung carcinoma: diffusion-weighted MR imaging—preliminary evaluation with apparent diffusion coefficient.2007;570-7.
  24. 24. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis.2004;2018-25.
  25. 25. Warth A, Cortis J, Soltermann A, Meister M, Budczies J, Stenzinger A, et al. Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role.2014;1222-9.
  26. 26. Tabata K, Tanaka T, Hayashi T, Hori T, Nunomura S, Yonezawa S, et al. Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered.2014;23-30.
  27. 27. Ahn HK, Jung M, Ha SY, Lee JI, Park I, Kim YS, et al. Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer.2014;5735-40.
  28. 28. Alper F, Kurt AT, Aydin Y, Ozgokce M, Akgun M. The role of dynamic magnetic resonance imaging in the evaluation of pulmonary nodules and masses.2013;80-6.
  29. 29. Karaman A, Kahraman M, Bozdoğan E, Alper F, Akgün M. Diffusion magnetic resonance imaging of thorax.2014;215-30.
  30. 30. Araz O, Demirci E, Ucar EY, Calik M, Karaman A, Durur-Subasi I, et al. Roles of Ki-67, p53, transforming growth factor-β and lysyl oxidase in the metastasis of lung cancer.2014;1034-9.
  31. 31. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013.2013;11-30.
  32. 32. Zhang Z, Zhou Y, Qian H, Shao G, Lu X, Chen Q, et al. Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells.2013;e633.
  33. 33. Schaarschmidt BM, Buchbender C, Nensa F, Grueneien J, Gomez B, Köhler J, et al. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI.2015;e0116277.
  34. 34. Yoshida S, Kobayashi S, Koga F, Ishioka J, Ishii C, Tanaka H, et al. Apparent diffusion coefficient as a prognostic biomarker of upper urinary tract cancer: a preliminary report.2013;2206-14.
  35. 35. Yoshida S, Koga F, Kobayashi S, Ishii C, Tanaka H, Tanaka H, et al. Role of diffusion weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer.2012;e21-e7.
  36. 36. Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.2012;1146-55.
  37. 37. Srinivasan A, Chenevert TL, Dwamena BA, Eisbruch A, Watcharotone K, Myles JD, et al. Utility of pretreatment mean apparent diffusion coefficient and apparent diffusion coefficient histograms in prediction of outcome to chemoradiation in head and neck squamous cell carcinoma.2012;131-7.
  38. 38. Pope WB, Lai A, Mehta R, Qiao J, Young JR, Xue X, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.2011;882-9.
  39. 39. Kıvrak AS, Paksoy Y, Erol C, Koplay M, Özbek S, Kara F. Comparison of apparent diffusion coefficient values among different MRI platforms: a multi-center phantom study.2013;433-7.
  40. 40. Rosenkrantz AB, Oei M, Babb JS, Niver BE, Taouli B. Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla.2011;128-35.
DOI: https://doi.org/10.1515/raon-2015-0032 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 250 - 255
Submitted on: Mar 11, 2015
Accepted on: Jul 9, 2015
Published on: Aug 21, 2015
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2015 Adem Karaman, Irmak Durur-Subasi, Fatih Alper, Omer Araz, Mahmut Subasi, Elif Demirci, Mevlut Albayrak, Gökhan Polat, Metin Akgun, Nevzat Karabulut, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.